SG11201900843WA - Synthetic retinoids (in cell modulation) - Google Patents

Synthetic retinoids (in cell modulation)

Info

Publication number
SG11201900843WA
SG11201900843WA SG11201900843WA SG11201900843WA SG11201900843WA SG 11201900843W A SG11201900843W A SG 11201900843WA SG 11201900843W A SG11201900843W A SG 11201900843WA SG 11201900843W A SG11201900843W A SG 11201900843WA SG 11201900843W A SG11201900843W A SG 11201900843WA
Authority
SG
Singapore
Prior art keywords
durham
international
university
road
pct
Prior art date
Application number
SG11201900843WA
Inventor
Andrew Whiting
Carrie Ambler
Mark Coles
David Chisholm
Original Assignee
Univ Durham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Durham filed Critical Univ Durham
Publication of SG11201900843WA publication Critical patent/SG11201900843WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 15 February 2018 (15.02.2018) WIPO I PCT omit VIII °nolo omolom mo Ho IHI niflom (10) International Publication Number WO 2018/029473 Al (51) International Patent Classification: A61K 31/435 (2006.01) A61P 31/04 (2006.01) A61K 31/47 (2006.01) A61P 31/12 (2006.01) A61P 35/00 (2006.01) A61P 31/00 (2006.01) A61P 17/06 (2006.01) (21) International Application Number: PCT/GB2017/052351 (22) International Filing Date: 09 August 2017 (09.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1613712.7 09 August 2016 (09.08.2016) GB (71) Applicant: UNIVERSITY OF DURHAM [GB/GB]; The Palatine Centre, Stockton Road, Durham DH1 3LE (GB). (72) Inventors: WHITING, Andrew; Department of Chem- istry, Durham University, South Road, Lower Mountjoy Durham DH1 3LE (GB). AMBLER, Carrie; Department of Bio sciences, Durham University, Stockton Road Durham DH1 3LE (GB). COLES, Mark; Centre for Immunology and Infection, University of York, Heslington, York North Yorkshire Y010 5DD (GB). CHISHOLM, David; Depart- ment of Chemistry, Durham University, South Road, Lower Mountjoy Durham DH1 3LE (GB). (74) Agent: GILHOLM, Stephen Philip; IPheions Intellectu- al Property, The Smithy Office, The Hawk Creative Busi- ness Park, Easingwold, YORK North Yorkshire Y061 3FE (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) 1-1 (54) Title: SYNTHETIC RETINOIDS (IN CELL MODULATION) N R 2 O A R 1 A 1 A2 C (57) : There are described novel compounds of formula I: (I) in which, in which A 1 , A 2 , A 3 , A 4 , R 1 and R 2 are each as herein defined, for use in the treatment or alleviation of an RAR mediated condition; and methods related thereto.
SG11201900843WA 2016-08-09 2017-08-09 Synthetic retinoids (in cell modulation) SG11201900843WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201613712 2016-08-09
PCT/GB2017/052351 WO2018029473A1 (en) 2016-08-09 2017-08-09 Synthetic retinoids (in cell modulation)

Publications (1)

Publication Number Publication Date
SG11201900843WA true SG11201900843WA (en) 2019-02-27

Family

ID=59969187

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900843WA SG11201900843WA (en) 2016-08-09 2017-08-09 Synthetic retinoids (in cell modulation)

Country Status (8)

Country Link
US (2) US11833203B2 (en)
EP (1) EP3496711A1 (en)
JP (1) JP7278208B2 (en)
CN (1) CN109843291A (en)
AU (1) AU2017310563B2 (en)
CA (1) CA3031889A1 (en)
SG (1) SG11201900843WA (en)
WO (1) WO2018029473A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201910239D0 (en) * 2019-07-17 2019-08-28 Lightox Ltd Fluorescent systems for biological imaging and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346016A (en) * 1980-04-23 1982-08-24 Ciba-Geigy Corporation 6-Styrylquinoxalines, and their use as fluorescent brighteners
GB0616961D0 (en) * 2006-08-29 2006-10-04 Univ Durham Retinoid derivatives
JP2010503615A (en) 2006-08-29 2010-02-04 レインナーベート リミテッド Retinoid compounds and their use
JP5280853B2 (en) * 2006-11-07 2013-09-04 Ａｇｃセイミケミカル株式会社 Novel amino group-containing aromatic compound and sensitizing dye for photoelectric conversion containing the aromatic compound
US8232273B2 (en) * 2008-12-19 2012-07-31 Genentech, Inc. Heterocyclic compounds and methods of use
ES2909874T3 (en) * 2014-10-10 2022-05-10 High Force Res Limited Fluorescent synthetic retinoids

Also Published As

Publication number Publication date
WO2018029473A1 (en) 2018-02-15
JP7278208B2 (en) 2023-05-19
EP3496711A1 (en) 2019-06-19
US20190209684A1 (en) 2019-07-11
US11324825B2 (en) 2022-05-10
US20190209685A1 (en) 2019-07-11
AU2017310563B2 (en) 2023-06-29
US11833203B2 (en) 2023-12-05
CN109843291A (en) 2019-06-04
CA3031889A1 (en) 2018-02-15
AU2017310563A1 (en) 2019-02-21
JP2019524809A (en) 2019-09-05

Similar Documents

Publication Publication Date Title
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201903155XA (en) Pharmaceutical compounds
SG11201805888SA (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SG11201804915RA (en) Methods for treating huntington's disease
SG11201900809TA (en) Combination steerable catheter and systems
SG11201809284UA (en) Mobile device connection apparatus
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201810485SA (en) Substituted carbonucleoside derivatives useful as anticancer agents
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201803676PA (en) Site specific her2 antibody drug conjugates
SG11201908678XA (en) Methods and compositions for reduction of immunogenicity
SG11201807720TA (en) Methods and systems for determining antibiotic susceptibility
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201908472VA (en) Compositions and methods for activating nk cells
SG11201908075UA (en) A microneedle device
SG11201809534UA (en) Methods of treating autoimmune disease using allogeneic t cells
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201903427UA (en) Deodorizing agent comprising zinc neodecanoate
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases